Products
Turoctocog alfa is commercially available as a powder and solvent for solution for injection (NovoEight). It has been approved in many countries since 2014. See also under turoctocog alfa pegol (pegylated drug).
Structure and properties
Turoctocog alfa is an activated human blood coagulation factor VIII produced by biotechnological methods and truncated at the B domain. It is a protein consisting of 1445 amino acids and has a molecular mass of approximately 166 kDA. Turoctocog alfa is a derivative of octocog alfa.
Effects
Turoctocog alfa (ATC B02BD02) replaces blood clotting factor VIII, which is not present in sufficient amounts, and thus enables blood clotting, i.e., the conversion of fibrinogen to fibrin and the formation of a blood clot. The drug thus prevents bleeding.
Indications
For the treatment and prevention of bleeding in patients with pretreated hemophilia A (congenital factor VIII deficiency).
Dosage
According to the SmPC. The drug is administered slowly intravenously.
Contraindications
- Hypersensitivity
For complete precautions, see the drug label.
Interactions
There are no known interactions with other drugs.
Adverse effects
The most common potential adverse effects include injection site reactions and elevated liver enzymes. Rarely, hypersensitivity reactions or allergic reactions have been observed.
